Ann Lab Med.  2019 Jul;39(4):406-410. 10.3343/alm.2019.39.4.406.

Multicenter Comparison of Four Automated Immunoassay Analyzers for Prostate Specific Antigen

• Park DJ
• Kim Y
• Lee HK
• Lee J
• Han K
• Kwon HJ

• KMID: 2438890
• DOI: http://doi.org/10.3343/alm.2019.39.4.406

Abstract

No abstract available.

MeSH Terms

Immunoassay*
Prostate*
Prostate-Specific Antigen*
Prostate-Specific Antigen

Figure

• 

  Fig. 1 Performance evaluation of four PSA automated analyzers using 120 samples. Passing-Bablok regression and Bland-Altman analysis of Immulite 2000Xpi and UniCel DXI 800 (A), Immulite 2000Xpi and ADVIA Centaur XPT (B), UniCel DXI 800 and ADVIA Centaur XPT (C), UniCel DXI 800 and ARICHITECT I2000SR (D), ARICHITECT I2000SR and ADVIA Centaur XPT (E), ARICHITECT I2000SR and Immulite 2000Xpi (F). Dotted lines in Bland-Altman plots indicate mean difference and mean difference±1.96 SD.Abbreviation: PSA, prostate specific antigen.

Reference

1. Bozeman CB, Carver BS, Eastham JA, Venable DD. Treatment of chronic prostatitis lowers serum prostate specific antigen. J Urol. 2002; 167:1723–1726. PMID: 11912396.

2. Sturgeon C. Tumor markers. In : Rifai N, Horvath AR, editors. Tietz textbook of clinical chemistry and molecular diagnostics. 6th ed. St. Louis: Elsevier;2018. p. 437–478. .

3. Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, et al. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract. 2004; 58:382–390. PMID: 15161124.

4. Kort SA, Martens F, Vanpoucke H, van Duijnhoven HL, Blankenstein MA. Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation. Clin Chem. 2006; 52:1568–1574. PMID: 16762996.

5. Critz FA, Williams WH, Holladay CT, Levinson AK, Benton JB, Holladay DA, et al. Post-treatment PSA < or=0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology. 1999; 54:968–971. PMID: 10604691.

6. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol. 2000; 163:1632–1642. PMID: 10799151.

7. Gheiler EL, Tefilli MV, Tiguert R, Grignon D, Cher ML, Sakr W, et al. Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology. 1998; 51:789–795. PMID: 9610593.

8. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006; 65:965–974. PMID: 16798415.

9. Ang M, Rajcic B, Foreman D, Moretti K, O'Callaghan ME. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL. BJU Int. 2016; 117(S4):68–75. PMID: 26890320.

10. Gontero P, Joniau S, Van Poppel H. Radical prostatectomy for PSA> or =100 ng/mL prostate cancer. Eur Urol. 2008; 54:957–958. PMID: 18433984.